FLT4 and neoplasm: Studies conducted on tumor tissue models attest to the clinically satisfactory effectiveness of drugs that slow down lymphangiogenesis by inhibiting VEGF-R3, the receptor that is the most specific to lymphangiogenesis [31, 34].